Cyto Immune Therapeutics, Inc. announced it raised $36.5 Million in an initial filing from an offering of $100 Million

Company

Location

About

CytoImmune Therapeutics is commercializing a coordinated immunotherapy platform for cancer treatments that combines chimeric antigen receptors (CARs) and bispecific antibodies (biAbs) with T cells and natural killer cells. This technology reduces the patient’s time to personalized treatment and enables optimized dosing with limited off-target effects. The company is developing product candidates targeted at treating acute myeloid leukemia, glioblastoma and multiple myeloma.